9
Phase 2–4 trials
Cardiomyopathy & ATTR amyloidosis · Live ClinicalTrials.gov data
Acoramidis (Attruby) clinical trial pipeline
ClinicalTrials.gov lists 9 phase 2–4 trials for acoramidis, 3 of them actively recruiting. The next phase 3 primary completion among them is expected Apr 2028. Refreshed daily — add up to four competitors to compare pipelines side by side.
6
Phase 3 trials
3
Actively recruiting
Apr 2028
Next phase 3 primary completion
2,283
Participants across trials
Eidos Therapeutics, a BridgeBio company
Lead sponsor by trial count
acoramidis (9)7 active2019–2039
acoramidis
'19
'21
'23
'25
'27
'29
'31
'33
'35
'37
'39
acoramidis
ATTRibute-CMP3
A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CMP3
Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)P3
AG10P3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantP3
ATTR-CMP4
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)P3
ACO-SWITCHP4
ASCEND-ATTRP4
Upcoming readouts
7 ahead · acoramidis
Select a trial to load its full ClinicalTrials.gov record.
Key acoramidis trials
Top 9 of the 9 registered phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07298044 | ACO-SWITCH — A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyret… | Phase 4 | Recruiting | Jul 2027 |
| NCT07306949 | ATTR-CM — Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers | Phase 4 | Recruiting | Mar 2028 |
| NCT07695701 | ASCEND-ATTR — Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis | Phase 4 | Not yet recruiting | Aug 2030 |
| NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers … | Phase 3 | Recruiting | Oct 2031 |
| NCT04988386 | AG10 — Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants | Phase 3 | Active, not recruiting | Apr 2028 |
| NCT07116473 | To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (… | Phase 3 | Not yet recruiting | Nov 2037 |
| NCT03860935 | ATTRibute-CM — Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy | Phase 3 | Completed | May 2023 |
| NCT04622046 | A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM | Phase 3 | Completed | Nov 2023 |
| NCT04882735 | Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) | Phase 3 | Withdrawn | Sept 2026 |
Related drug pipelines
FAQ
- How many clinical trials are running for acoramidis?
- ClinicalTrials.gov currently lists 9 phase 2–4 acoramidis trials: 0 phase 2, 6 phase 3, and 3 phase 4. 3 are actively recruiting.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare acoramidis against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.